A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in PONV

Inclusion criteria

• Age ≥18 and ≤75 years old, male or female;
• The American Society of Anesthesiologists (ASA) Class I-III;
• 18 kg/m2 ≤ BMI ≤ 40 kg/m2;
• Hospitalized subjects scheduled to undergo elective laparoscopic abdominal or gynecological surgery under general anesthesia for an expected anesthetic time of ≥ 1 h;
• Subjects with intermediate or high risk (score ≥ 2 points) experiencing PONV judged by the investigator using the Apfel simplified risk score;
• Subjects who agree to participate in the trial and voluntarily sign the Informed Consent Form (ICF);

Exclusion criteria

Prior and concomitant diseases

• History or evidence of any of the following diseases prior to screening:

• Respiratory diseases: severe chronic obstructive pulmonary disease, acute exacerbation of chronic obstructive pulmonary disease, severe airway stenosis, large pharyngolaryngeal mass, (broncho) tracheoesophageal fistula or airway tear, and serious respiratory tract infection within 2 weeks prior to screening;
• Central nervous system disorders: subjects with epilepsy, Parkinson's disease, or other central nervous system diseases causing nausea and vomiting, such as craniocerebral injury, intracranial space-occupying lesions, intracranial aneurysms, etc.;
• Cardiovascular diseases: subjects with uncontrolled hypertension [systolic blood pressure (SBP) ≥170 mmHg and/or diastolic blood pressure (DBP) ≥105 mmHg without treatment with antihypertensive medication, or SBP ≥160 mmHg and/or DBP ≥100 mmHg after treatment with antihypertensive medications], serious cardiac insufficiency ( the New York Heart Association [NYHA] Grade III-IV), unstable angina pectoris, acute myocardial infarction, severe arrhythmia, history of tachycardia/bradycardia requiring medical treatment, Grade II-III atrioventricular block (excluding pacemaker use) within 6 months prior to screenin;
• Digestive disorders: subjects with intestinal obstruction or other digestive diseases that may cause nausea and vomiting as judged by the investigator;
• Patients with a confirmed diagnosis of vestibular function disorder, excluding travel sickness (including but not limited to peripheral vestibular syndrome, central vestibular syndrome, etc.);
• Subjects with a history of significant and chronic dizziness.

Prior and concomitant medications

• Any of the following medications or treatments have been used at screening:

• Subjects who have received antiemetics/medications with antiemetic effects within 24 h before the start of surgery or who have used antiemetics/drugs with antiemetic effects before the start of surgery for no more than 5 half-lives (calculated as the longest time);
• Subjects with neoplasm malignant treated with chemotherapy within 4 weeks prior to screening;

Laboratory and other tests

• Laboratory test indicators at screening meet the following criteria:

• White blood cell count < 3.0 × 109/L;
• Platelet count < 80 × 109/L;
• Hemoglobin< 70 g/L;
• Prolongation of prothrombin time (PT) exceeding the upper limit of normal for 3 seconds;
• Prolongation of activated partial thromboplastin time (APTT) exceeding the upper limit of normal for 10 seconds;
• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 3 × ULN;
• Total bilirubin > 2 × ULN;
• Blood creatinine > 2 × ULN;
• Fasting serum glucose≥ 11.1 mmol/L;

Other conditions

• Subjects anticipated to require continued endotracheal intubation after the end of surgery;
• Subjects anticipated to require the insertion of nasal or oral gastric tubes after the end of surgery;
• Subjects with a history of serious drug allergies or those allergic to the investigational drugs specified in the protocol;
• Subjects with a history of drug abuse, drug addiction, or alcoholism within 3 months prior to screening, where alcoholism is defined as consuming > 2 units of alcohol on average daily (1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor with 40% alcohol or 150 mL of wine);
• Subjects with nausea, retching, or vomiting within 24 h prior to induction of anesthesia (except for those caused by bowel preparation);
• Subjects who have participated in any investigational trial (defined as receiving investigational drug or placebo) within 3 months prior to screening;
• Female subjects who are pregnant or breastfeeding; female or male subjects of child-bearing potential are unwilling to use contraception throughout the entire study period and for 3 months after the study completion;
• Subjects judged by the investigator to be unsuitable for participating in this clinical trial for any other factors.